免费文献传递   相关文献

Biocatalysis and green process for chiral pharmaceutical chemicals

手性医药化学品生物催化合成进展与实践



全 文 :!11
"!

#
2013
$

%
&
 

 
(
 
)
 
*
 
+
ChineseJournalofBioprocessEngineering
Vol.11No.2
Mar.2013
doi:10.3969/j.issn.1672-3678.2013.02.004
!"#$
:2013-01-04
¯°±²

yzQ?C:;LMȀ
(863
Ȁ
)(2012AA022201)
%&(

Ÿ y
(1961—),
/

ëì

‚³h4

:;<=

&E\p&*,Email:zhengyg@zjut.edu.cn
õô*+Ùf¡+,,ÙÃLø3c£-
^_%
,`
Ga

bO6E78 &6[cde &f5g&h5ijk6[cd$,

Hl
310014)
9
 
:

®¯()°f±²‘()°f³=®¯´µ«,¶·`£EF¸¹¯°f,i«)_º&MN

»¼
°fZ½u
、¸
¹¯z/‡[¾¿À/kh3

Á4‚

()°f*+ÃÄÅÆ

ÇÈ%Él]”Ê@tËMN
̚,~ÍÎÏ

~Ÿ®¯ÐËfO”ÑÒÓÔÕÖ×Ø,!–&»

Ùڝž%()°fÛ/O+01,i
¬…

<ÜÝÙÚL®¯Ë)()°fÝ~,“fÞ0>ß

à€%ás,01P…

;<=

®¯Ë)

()°f

­&N

ÑÒÓË
>?@AB
:TQ46    
CDEFG
:A    
CHIB
:1672-3678(2013)02-0024-06
Biocatalysisandgreenprocessforchiralpharmaceuticalchemicals
ZHENGYuguo,SHENYinchu
(EngineeringResearchCenterofBioconversionandBiopurificationoftheMinistryof
Education,InstituteofBioengineering,ZhejiangUniversityofTechnology,Hangzhou310014,China)
Abstract:Enantioselectivebiocatalysisisamodernmaterialprocessingtechnologybasedonthe
recognitioncapabilityofbiocatalysttochiralmolecularconfiguration,ithadmajoradvantagesofhigh
eficiency,highselectivityandambientreactionconditions.Inthelast10years,rapidadvancesinlarge
scaleDNAsequencingandenzymedirectedevolutionrenderedbiocatalysisasnecessarysynthetictoolin
greenpharmaceuticalprocess.Severalsuccessfulexamplesweregivenandabiocatalyticprocesswas
developedtoreplaceexistingchemicalroutesforblockbusterdrugs.Advancesinsynthesisofchiral
pharmaceuticalchemicalsbybiocatalysiswereanalyzedcombinedwithresearchexperiencesinrecent
yearsanddevelopmentdirectionsoftheareawerepointedout.
Keywords:chiraldrugs;biocatalysis;enzymeengineering;greenpharmaceuticalprocess
  
·…JE\)WmPQ

R„ayÚyõ£ú
[…`«STú)B£¤{NTÄ

&E\?
Cm£ú)B{N2ZÎTLMôv

¢þm*+
Ý¢

,¡5lmN£ú)W{L²Žu‚^Ä

yÆAB¼ydÇlm\}gOF

u‚ýÜB
Ö{»I

pž$²&ã

&E\×ب¡Ž

Úu‚*+
:①&E\LâD\}z~*+)+
9ÈI7›ÀN•ÀjN

ùª™tÂÛ]j
N

LIzXN)s
;②&E\TÄefð(S
^ItžN&E\¹kÈCªUV*=(Sn
ª6

nUî~Qq¨N*+±²„kÈA«N&
E\¹

+®J£¹iùú£¤8BNLM{IÔ2
UÙ&E\”£ú)Bœ½Íæ¹uÖNU
«
[1]。
ª=S
2002
$N¢h“&E\:”“}
~
Codexis,
þ
2011
$J£¹i&q^NTVó
¾¹
4900
ؼ”

@ÀŠWvœG™ùú~!‘
\}^£¤8B

Ú}
Codexis
NÇÈ

þC^8
B

"
AmpacFineChemical、DishmanPharmaceutical
&Chemicals、Lonza
~
DSM
a‰&q
10tCodexis
u
Û:LNJÄSùú{4rN£¤

Ú·bü<
iNùú\}^PTŠ"
BASF、Kaneka、Almac
Sciences、Novasep
~
FabbricaItalianaSintetici

‡ª=Ž&E\:Lœ|

Õ¸

&E\X›
NŠÞE&Ž&8BCÙuB~:”8BY¡

"
Cambrex
«À
IEP,PACS
«À
Protéus,Johnson
Mathey
«À
Xzyme,Codexis
èCَ
JülichFine
Chemicals、Enizis
~
BioCatalysis。
&E\?CNLM³´Dph׿¬LIGN

!b

5“Dú_`“~úÎN%


&E\DB5“ú~{4r•t²%N
5a›b
[2]。
ɲ

yõölm¨LN
1200

{

t
820
IWS5“ú

5“úNãäÁÀ˜
ÐbPöX„
80%
ËÌ

2bR‡rúN&qm
£ú)B{Ùt;„;u‚NýÜ

&E\D8
Ä&E\¹R5“GHà)N=-U†Ð{
jN“E\N-()*+

m5“Cª{stö,




&E\6TZ„_›“?C+_

?
Crc½[½ñ
,¨
L~¼Äª623ïn

"+Â
+Y}k|N(Ad{ËL¡)BJ)sX?
C
、¯
vN—=Ð\~Qèìij?C

JQÎh¾
?C

øü?C¼JE\¹NFUKñ~n£]ª
6ª™IU

…@)B&E\NbySGI

è*J‹“§\#”a?C

by®)JN
FU©G&RIܐ

!¿

lm\}Œ]”N-
()ef

º=rjN“·

&E\´st^PN
\}~wØjN“

KTôMX~

<=ÆÇCª{
NPà、
í©\~uòa¨KT

ö÷t^u‚W

*/‚WE\¹~^™KTü-~G^‘\q¸
tÞY¹N¼Ä
[3],
+ù23çQéHGH“

ön
*+NYZAH
(E factor)[4]。
1 
+,,فõô*+Ùf¡./•
–>¾Ë/01c01
  
&E\m5“ùú\}^&q{Tĕs
e、
?Crc•™½¸NäHÊWβי®
-&ÓNCª

›_
DSM
}~ml×Øގvì
)^

ѪŽcÇN\}

&E\pbr\?
C
[5]。
¿D

ڐN

:(<=¥‡
(6
APA)、7
:(…)¥‡
(7 ACA)、7
:(ᑗ
à(…)¥‡
(7 ADCA)
NJ_£]

ˆi<=Ó

—\J
、D
:(‡à\J~<Ÿ—(—\Ja

h$qìÛ*
10000t
N
6 APA
™ä

ÆÇ\}ê
­_±¼Ä¿o(`–¥
(TMSCl)
˜<=Ó


?

ÐbPp
PCl5KT&ª`¢˜™,âGê­
¹
6 APA(
#
1)。
l)Wm
40℃
×Ð{

œ¼Ä
éê\}^
PCl5~CH2Cl2、nBuOHatÞY¹,Ê
&q
1kg
q^

q&
10~100kg
ç

l)W†¹
20
¾
90
$¢J_)WLMÀÁÅÝ¢

çö
÷

3
[6]。βי®-&ÓNVŒ" D (Ra
(

p1:‡†,¡ŽJ_&q

}UVLÕ

ˆ
i¦*\J

ÌAJ

z¼Ja

•À

NpVŒ
NŒ°†Dð<=ӗ\J,¡N

(i)TMSClthenPCl5,PhNMe2,CH2Cl2,-40℃;
(i)nBuOH,-40℃,thenH2O,0℃;
(ii)Penacylase,H2O,37℃
?
1 
234

/Ùf6)ß567Ù
Fig.1 DeacetylationofpenicilinGbychemical
andenzymaticmethods
Á$„

yõöY¡Žvì&E\?CK¤
ST <úCª)WNsä

h
1),
ÐbP2ZŽ
l?Cmlm£ú{NŸ†

"
2012
$/¼yd
Çlm\}gOF5lmCªUVFìb
Codexis
}~ ¨ L N — ( * ‰ J _ C ª 6 c t d
(Simvastatin)
UV
[7]。
6ctdDhectd
(Lovastatin)
™ù

mectdVŒo

ÜBk(

Úo(

mÆÇCª)W{

¿˜ectdê­
™f¢xÞ
J(MonacolinJ),
ÐbPè*ý、
¿
52 
!

# Ÿ ya

5“ùú\}^&E\CªÐMp,´
o(–¥\¶?
C11
~
C13
Üa(

¶?Nf¢


Gα Ÿo(¢—`—\À&ª¶?N6c
td

âGá¶?¹6ctd

l)WAfqì
÷S
70%,´
±¼Ävìtþt^N¹
[8]。
¼y
(×v}eghG³N
YiTang
ëì6ÂLԎh
„iuectd&Cª(AjN—(*‰J
LovD
™E\¹N6ctdRCª”)W
[8]。

ÀN)W¿ê­ectdªêY“Nf¢xÞ

kl

m
LovD
E\×p—(Pr α Ÿo(¢—

o(m¤‡½
(DMB S MMP)
KT&ªLYS
êN6ctdkl

f¢xÞ

-ì4/™
75g/L
¸

6ctdklNq:Û*
97%,
2ZŽ”)W
[vN^;“

6ctd\}~J_Cª)Wã
("#

³Z

!
1 
+,,Ù-.Ë8+b9@X—:;<=+,
Table1 Biocatalyticproductionofmajordiseasesdrugs
}~ Š^i
èÄi
(API)
2011
$
TVó

Δ
&E\¹
Pfizer Lipitor atorvastatin
n
9577
Ketoreductase,
halohydrin
dehalogenase
Pfizer Lyrica pregabalin
n
3693 Lipase
Merck&Co.Inc Singulair montelukast
n
5479 Ketoreductase
Merck&Co.Inc Januvia sitagliptin
n
3324 Transaminase
Merck&Co.Inc Zocor simvastatin
n
456 Acyltransferase
Merck&Co.Inc Victrelis Boceprevir
n
140 Amineoxidase
Merck&Co.Inc Crixivan indinavir
n
192 Toluenedioxygenase
Merck&Co.Inc Emend Aprepitant
n
419 Alcoholdehydrogenase
GlaxoSmithKline Paxil paroxetine £ 435 Protease
 
?
2 
>?@AÙf6)ßÃL)BCD
Fig.2 Comparisonofsimvastatinsynthesisprocessbychemicalandenzymaticmethods
2 
+,,ÙÃLõô*+Ùf¡b*
Ù 2£-
  
úû:;6Â0o‚Q3éâú£¤Nq
B^

myÃ(p¨MŽ&E\Cª5“ùú
\}^N(S~TÄ:;

m
C—N
Å­J

¦*J

à\´éJ

=qJ~z¼Ja5“E\ގbü)^

62
&
 

 
(
 
)
 
*
 
+
  
!
11
"
 
2.1 
…EFGH34+,,ÙÃLGH3IJ
ÄÏ=ÓDÉyuÛLÔÙve&qN!
bÚûÄ-&Ó

b†Drûês\týNj
^I

þtÎBG

GyPê­
、C—N
Å­ÀN
qÄÏ=ˆ™D”b¢J£¹®wuýûüú
N%{4r

úû:;6ÂijBQÎE
\Å­ÄÏ=Ó&qÄÏ=ˆ™NF&”’
Æ

ÄÏ=Ó

¿mw‹JN^Ä×

ꭙÄ
Ïa™~:;w

ÄÏa™G*:;w

$=
>J=>À

âè*
C—N
%Å­JN—=Å­

¹ÄÏ=Ǚ

ÄÏ=ǙÐbPG\}C
ª

¹ÄÏ=ˆ™
[9-10](
#
3)。
:;ŽQ‘/
ÄÏ=ÓÅ­qG^<_

ÈWŽ)WR+

­
–ŽG^ɯ

q^«:+
31%
çQ¹
76%
h
ö

j=Ž+ÄÏ=Ó¹ÄÏ=ˆ™N&Eê­Å­qB\?C

?
3 
+,,ÙK’GH34

ÃLGH3IJ
Fig.3 ProductionofvalienamidefromvalidemycinAbymicrobialhydrolysisandlysis
2.2 
LMÃ)

7J)N)æO•P
(S)(+) 2,

QR¯STUR7J
  
¡~t¢£DQÎNv=>Ÿ2J

»£¹

p
˜™‘åN2-Dɲ-uw8ñNjú

êµ
±²Öx
。(S)(+)2,2
Ÿo(Y¤¥o—™D¡
~t¢£N%5“{4r

Ùþéâª6N
1/3
h
ö

"#
(S)(+)2,2
Ÿo(Y¤¥o—™QÎC
ª?CR¤£¡~t¢£Nª6stu‚wx

ɲ)BöTÄN\}Cª)WKTPyy

ôMz{

«:n

LÛ*
10%),
œ*+¼Ävì
tþt^Y¹

YZðñeu

éHGH“n

ú
û³m,Iãh
2,2
Ÿo(Y¤¦™ù
,¨

¦êCJ

—™J§J6¶
(S)(+) 2,2
Ÿo(
Y¤¥o—™Cª”)W

#
4)[11-12]。
l)WN
$Æ*\:¾¹
47%


q
e.e.
òvS
99%;
xy¨qª«À

nC«:¾¹
72%


ù
œ

è*)W:”

+V…ö_ºŽtþt^Y¹
N¼Ä

¿çòóìvvö÷

2.3 
VW)

X),ÙÃLYZ[\õô>]Z
ÃQßÞ

Š^iŽQ>
(Lyrica))
ÆöêÅ
¼y
FDA
$ÛÄSü~|}À~G

wuý·o
?
4 
N)æOߕP
(S)(+)2,2
QR¯
STUR7J
Fig.4 Nitrilehydratase/amidasecoupledsynthesisof
(s)(+)2,2,dimethylcyclopropanecarboxamide
~G

€

[\‚a

yõƒ}F
(IASP)、
»$~GýA}F¶„
(EFNS)
~!yy=-&p
ö´:;³
(NICE)
ayÚyõ>0§å‰Õ\…
ÃQßޙbVûüú

PQ}~¨LNh·
í©

†‘(

‡(

o(ˆ‡‘½
(CNDE)
™ù

Gz¼J=rjN“ê­

âGéܪR


¦“ê­

(>´é£ÃQßÞ

#
5)
N} J_)WDɲ•™¿ÐNÃQßÞCª)W

Úþ³Ä&‰GÄJ™„VS
Novozymes
}~N
Š^\z¼J
Lipolase(TLL,
„V
Thermomyces
lanuginosus),
©Éä&¥8¶?

72 
!

# Ÿ ya

5“ùú\}^&E\CªÐMp,´
?5 
Ùf )ßÃLYZ[Fig.5 ChemoenzymaticsynthesisofPregabalin
  
úûk¯BG²#vìij

+Š‹{G^
¹bÆUeQ=rjN“ê­
CNDE

(S) 2
†‘(

‡(

o(ˆ‡N½Jq&’
MorgarelamorganiZJB 09203[13]。
è*=KTr
c{Ñ(¯æ^H:z

I23­ºq»£¡
³

q4/¾¹
045mol/L,
R‡r*ìò
(e.e.
ò
)>98%,
R‡rjN:

ò¾¹
92。
Õ¸n+
ThermomyceslanuginosusDSM10635
{„i¹LÕ
S
TLL
NÎz¼J
LIP,
†I

)jN“ê­
CNDE,e.e.
ò
>99%,
GyBŒ~U+

U+r
S88T/A99N/V116D
N‹†ãÍ&)çQ
58
3
[14]。
2.4 
^_?@A`a+,,ÙÃL
td®úUt룍}ˆCª

23ïn
OŽ,@8ýNL&

©ª™]p‘\8ýû
üN(Sú

td®úNTVóQ¾`«ù
úêµdTVóN
55%,
myõùúêµöST
N®®ï,zú{ÖS׿ýÜ

mIhÜÙ
N˜„

td®ïzú˜DyõùúêµöNu
’“”


‡(
(3R,5R)
Ÿa(
3,5 O
˜P¤(
ˆ‡•¢½
(TBIN)
™®Itd®úN%{4
r

Ö{ÄS®Itd®úNCª
,`
«$±²
ìÛ*
1000t。
…octdCªR
TBIN
<}‘/
‚²ýQ

R‡r*ìò~xR‡r*ìò
(d.e.
ò

G-Û*
995%
~
99%。


Q<}‘/
TBIN
NQΣ]?Cb†Dtd®úqBNu
‚NO?C

yÃ@ÄN
TBIN
\}Cª?CÏm
h×Xô

±‚¼Ä–¥

l¢(—~nS
-70℃
ÿ˜ôM

Ïm™“¢ê

xR‡M6LÄG

q
d.e.
òn

KTѪN–\çè A±‚G*
š›NK2oˆœñ

ĮCDa

úûk¯B¨LŽ
TBIN
J \}BCCªU
V

#
6)。
”)WjNÒNŸ5“¹


—‘‡‘½
(ATS 3)
™¨Léâ

Gž(´éJL
RX´éCª
(S) 4
`

a(¢‡‘½
(ATS 4)。ATS 4
Gqˆ=qJE\¹
(R)

‡(

a(¢‡‘½
(ATS 5),
Àûp‘‡•
¢½L&Å¢KT


(R) 6
‡(

a(

ž(ˆ‡•¢½
(ATS 6)。300g/LATS 6
G

ž(´éJLRX´é
2h,
ù*\:
100%,
q


‡(
(3R,5R)
Ÿa(ˆ‡•¢½
(ATS 7)
e.e.
ò
>995%,d.e.
ò
>990%。ATS 7
G
2,2
Ÿoà(¤¥¶?£<}‘
TBIN(ATS 8)。
l
J \}BCCª)WŸù_ºŽ–¥

l¢(—~
ÿ˜ôM

q<}‘/Q
,¨
q

çâì


Äì~Uîv./ïn

st23N^;“

?
6 
) ÙfßÃL
TBIN
Fig.6 PreparationofTBINbychemoenzymaticmethod
82
&
 

 
(
 
)
 
*
 
+
  
!
11
"
 
3 
ybª
+¼y
FDA
ú^}}8ëâ„3
,2011~2014
$˜Dú^¥8¹#NQr#

ˆiöGÚú^N
80
MNO¥8
,2014
$ú^¥8¹#}옾¹ 
r


186
M

øü¥8¹#ú˜*ó[vNê
µÆ4


,¨
Llm

QÎNQ3éâú&
E\)WstÖxNTÄ~êµ²%

ºŽÆÇ
Nê­J®"z¼J

½J

½¾J

=qJ

—J

—™J

Yà\ê­Ja·

JE\à、
q
¢

:(*‰
、C—C
%6¶
、C—C
§%´é˜DÁ
ÀN”<=

m5“ùú\}^UVuà*+{

Õ¸°¡\}~&}<_

ñS+OCªG¶Ì
/kÈQÎN\} &E\Y¶)W+„u
‚

ß·

éâú{5“oéHNky

*+¨L
o#NÈWa†.&E\税”NgO

­®CD

[1] ThayerAM.Biocatalysis[J].ChemEngNews,2012,90(22):
1318.
[2] PatelRN.Syntheisofchiralpharmaceuticalintermediateby
biocatalysis[J].CordChemRev,2008,252:659701.
[3] 
L¢.

Þy¯

77

a

5“p5“ú:;{N£ >
}®¯
[J].
{y>}(‚
,2003,17(2):7275.
[4] TaoJH,Xu JH.Biocatalysisin developmentofgreen
pharmaceuticalprocess[J].CurOpinChemBiol,2009,13(1):
4350.
[5] BrugginkA.β י®-&ÓNCª:\}、&E\p 
Abr[M].
hA¤

<|Ô

¥

¦®

̧¨¨E
,2010.
[6] DunnPJ.Theimportantceofgreenchemistryinprocessresearch
anddevelopment[J].ChemSocRev,2012,41(4):14521461.
[7] XiongYD,


ª«
.2012
$¼ydÇlm\}gOF1
ü
[J].
\)ÐM
,2012,31(9):21102011.
[8] XieXK,TangY.Eficientsynthesisofsimvastatinbyuseof
wholecelbiocatalysis[J].ApplEnvironMicrobiol,2007,73
(7):20542060.
[9] ZhengYG,ZhangXF,ShenYC.Microbialtransformationof
validamycinAtovalienaminebyimmobilizedcels[J].Biocatal
Biotransform,2005,23(2):7177.
[10] ZhangJF,ZhengY G,XueY P,etal.Purificationand
characterizationoftheglucoside3dehydrogenaseproducedbya
newlyisolatedStenotrophomonasmaltrophiliaCCTCCM204024
[J].ApplMicrobiolBiotechnol,2006,71(5):638645.
[11] WangYJ,LiuZQ,ZhengRC,etal.Screening,cultivation,and
biocatalyticperformanceofRhodococcusboritoleransFW815with
strong2,2dimethylcyclopropanecarbonitrilehydrataseactivity
[J].JIndMicrobiolBiotechnol,2012,39(3):409417.
[12] ZhengRC,WangYS,LiuZQ,etal.Isolationandcharacterization
ofDelftiatsuruhatensisZJB05174,capableofRenantioselective
degradationof2,2dimethylcyclopropanecarboxamide[J].Res
Microbiol,2007,158(3):258264
[13] 
Ÿ y

Ÿ¬z

­KÐ

a

¬®¬’im£]
(S) 2
†
‘(

‡(

o(ˆ‡{NTÄ

{y
,201110318750.
X[P].20111019.
[14] 
Ÿ y
,¯
–º

­KÐ

a

°±~ο)’z¼JU+
r

²³(AiþTÄ

{y
,201210407833.0[P].2012
1023.
92 
!

# Ÿ ya

5“ùú\}^&E\CªÐMp,´